Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ER positive
i
Other names:
ESR1, Era, ESR, NR3A1, ER, ER beta
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2099
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
ER positive
Endometrial Cancer
ER positive
Endometrial Cancer
abemaciclib
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 1 week (New C3)
abemaciclib
Sensitive
:
C2
J Clin Oncol - 1wk
abemaciclib
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 1 week
abemaciclib
Sensitive
:
C2
J Clin Oncol - 1 week - (New C3)
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
CFI-402257
Sensitive: B - Late Trials
Treadwell Therap Press Release - 3 weeks (New B)
CFI-402257
Sensitive
:
B
Treadwell Therap Press Release - 3wk
CFI-402257
Sensitive: B - Late Trials
Treadwell Therap Press Release - 3 weeks
CFI-402257
Sensitive
:
B
Treadwell Therap Press Release - 3 weeks - (New B)
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
exemestane
Sensitive: A1 - Approval
exemestane
Sensitive
:
A1
exemestane
Sensitive: A1 - Approval
exemestane
Sensitive
:
A1
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
toremifene
Sensitive: A1 - Approval
toremifene
Sensitive
:
A1
toremifene
Sensitive: A1 - Approval
toremifene
Sensitive
:
A1
ER positive
HER2 Positive Breast Cancer
ER positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
trastuzumab + lapatinib
Sensitive
:
A2
trastuzumab + lapatinib
Sensitive: A2 - Guideline
trastuzumab + lapatinib
Sensitive
:
A2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
anastrozole
Sensitive: A2 - Guideline
anastrozole
Sensitive
:
A2
anastrozole
Sensitive: A2 - Guideline
anastrozole
Sensitive
:
A2
ER positive
Male Breast Cancer
ER positive
Male Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
tamoxifen
Sensitive: A2 - Guideline
tamoxifen
Sensitive
:
A2
ER positive
HER2 Positive Breast Cancer
ER positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A2 - Guideline
neratinib
Sensitive
:
A2
neratinib
Sensitive: A2 - Guideline
neratinib
Sensitive
:
A2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
CDK6 inhibitor
Sensitive: A2 - Guideline
CDK6 inhibitor
Sensitive
:
A2
CDK6 inhibitor
Sensitive: A2 - Guideline
CDK6 inhibitor
Sensitive
:
A2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
CDK4 inhibitor
Sensitive: A2 - Guideline
CDK4 inhibitor
Sensitive
:
A2
CDK4 inhibitor
Sensitive: A2 - Guideline
CDK4 inhibitor
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
gimeracil/oteracil/tegafur
Sensitive: B - Late Trials
gimeracil / oteracil / tegafur
Sensitive
:
B
gimeracil/oteracil/tegafur
Sensitive: B - Late Trials
gimeracil / oteracil / tegafur
Sensitive
:
B
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: B - Late Trials
palbociclib
Sensitive
:
B
palbociclib
Sensitive: B - Late Trials
palbociclib
Sensitive
:
B
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
cyclophosphamide + thiotepa
Sensitive: B - Late Trials
cyclophosphamide + thiotepa
Sensitive
:
B
cyclophosphamide + thiotepa
Sensitive: B - Late Trials
cyclophosphamide + thiotepa
Sensitive
:
B
ER positive
HER2 Positive Breast Cancer
ER positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
trastuzumab
Sensitive
:
B
trastuzumab
Sensitive: B - Late Trials
trastuzumab
Sensitive
:
B
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
GDC-0032
Sensitive: B - Late Trials
GDC-0032
Sensitive
:
B
GDC-0032
Sensitive: B - Late Trials
GDC-0032
Sensitive
:
B
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: B - Late Trials
ribociclib
Sensitive
:
B
ribociclib
Sensitive: B - Late Trials
ribociclib
Sensitive
:
B
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive: B - Late Trials
palbociclib
Sensitive
:
B
palbociclib
Sensitive: B - Late Trials
palbociclib
Sensitive
:
B
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
EC-P
Sensitive: B - Late Trials
EC-P
Sensitive
:
B
EC-P
Sensitive: B - Late Trials
EC-P
Sensitive
:
B
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
elacestrant
Sensitive: B - Late Trials
elacestrant
Sensitive
:
B
elacestrant
Sensitive: B - Late Trials
elacestrant
Sensitive
:
B
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
elacestrant
Sensitive: B - Late Trials
elacestrant
Sensitive
:
B
elacestrant
Sensitive: B - Late Trials
elacestrant
Sensitive
:
B
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
OP-1250
Sensitive: B - Late Trials
OP-1250
Sensitive
:
B
OP-1250
Sensitive: B - Late Trials
OP-1250
Sensitive
:
B
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
exemestane
Sensitive: C1 - Off-label
exemestane
Sensitive
:
C1
exemestane
Sensitive: C1 - Off-label
exemestane
Sensitive
:
C1
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: C1 - Off-label
fulvestrant
Sensitive
:
C1
fulvestrant
Sensitive: C1 - Off-label
fulvestrant
Sensitive
:
C1
ER positive
Breast Cancer
ER positive
Breast Cancer
capecitabine
Sensitive: C2 – Inclusion Criteria
capecitabine
Sensitive
:
C2
capecitabine
Sensitive: C2 – Inclusion Criteria
capecitabine
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
Z-endoxifen hydrochloride
Sensitive: C2 – Inclusion Criteria
Z-endoxifen hydrochloride
Sensitive
:
C2
Z-endoxifen hydrochloride
Sensitive: C2 – Inclusion Criteria
Z-endoxifen hydrochloride
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
SAR439859
Sensitive: C2 – Inclusion Criteria
SAR439859
Sensitive
:
C2
SAR439859
Sensitive: C2 – Inclusion Criteria
SAR439859
Sensitive
:
C2
ER positive
Ovarian Cancer
ER positive
Ovarian Cancer
ribociclib
Sensitive: C2 – Inclusion Criteria
ribociclib
Sensitive
:
C2
ribociclib
Sensitive: C2 – Inclusion Criteria
ribociclib
Sensitive
:
C2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
capecitabine
Sensitive: C2 – Inclusion Criteria
capecitabine
Sensitive
:
C2
capecitabine
Sensitive: C2 – Inclusion Criteria
capecitabine
Sensitive
:
C2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
ZN-c5
Sensitive: C2 – Inclusion Criteria
ZN-c5
Sensitive
:
C2
ZN-c5
Sensitive: C2 – Inclusion Criteria
ZN-c5
Sensitive
:
C2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login